Cioteronel

Cioteronel (INN, USAN) (developmental code name CPC-10997; former tentative brand names Cyoctol, Ethocyn, X-Andron) is a nonsteroidal antiandrogen (NSAA) that was never marketed.[1][2][3] It was under development between 1989 and 2001 for the topical treatment of androgenetic alopecia (male pattern baldness) and acne and for the oral treatment of benign prostatic hyperplasia; it reached phase III clinical trials for acne and phase II studies for androgenetic alopecia, but was ultimately discontinued due to poor efficacy.[3][4]

Cioteronel
Clinical data
Other namesCPC-10997; Cyoctol; Ethocyn; X-Andron
Routes of
administration		By mouth, topical
Drug classNonsteroidal antiandrogen
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC16H28O2
Molar mass252.39232 g/mol g·mol−1
3D model (JSmol)

See also

References
  1. C.R. Ganellin; David J. Triggle (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 570–. ISBN 978-0-412-46630-4.
  2. Daniel Lednicer (21 November 1994). The Organic Chemistry of Drug Synthesis. John Wiley & Sons. pp. 11–. ISBN 978-0-471-58959-4.
  3. Tiwari, Atul; Krishna, N S; Nanda, Kamna; Chugh, Anita (2005). "Benign prostatic hyperplasia: an insight into current investigational medical therapies". Expert Opinion on Investigational Drugs. 14 (11): 1359–1372. doi:10.1517/13543784.14.11.1359. ISSN 1354-3784.
  4. https://adisinsight.springer.com/drugs/800003205%5B%5D


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.